

APPENDIX OF AMENDMENTS

16. (Twice amended) The crystallizable co-complex according to claim [13] 15, wherein said first protein kinase is p38, said second protein kinase is a MAP kinase and said inhibitor is a pyridinyl-imidazole inhibitor of p38.

17. (Amended) The co-complex according to claim [13] 15, wherein said pyridinyl-imidazole inhibitor of p38 is selected from SB203580 or SB202190.

REMARKS

The Claim Amendments

Applicants have amended claims 16 and 17 to correct their dependency.

Applicants have added claims 18-22. Support for claims 18-22 may be found throughout the specification. See, e.g., page 6, lines 4-16, page 13, lines 13-19, page 32, lines 18-23 and originally-filed claims 10-14.

None of these amendments adds new matter. Their entry is requested.

Respectfully submitted,

Karen E. Brown

James F. Haley, Jr. (Reg. No. 27,794)

Attorney for Applicants

Karen E. Brown (Reg. No. 43,866)

Agent for Applicants

c/o Fish & Neave

1251 Avenue of the Americas

New York, New York 10020-1104

Tel.: (212) 596-9000

Fax: (212) 596-9090

I hereby certify that this
communication is being
deposited with the U.S.
Postal Service by First
Class Mail in an envelope
addressed for delivery
FIRST CLASS PER
MAIL

WASHINGTON, D.C. 20231 on

February 26, 2001

Lori N. Scott

Lori N. Scott
Signature of Person Signing